Search Tips
of 1 Next >
Results Found: 3
  • Tumors with TRK fusions (MSK, 2019): Tumors with TRK fusions based on MSK-IMPACT targeted sequencing.

    Description

    This dataset contains summary data visualizations and clinical data from a broad sampling of tropomyosin receptor kinase (TRK) fusion tumors. The data was gathered utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), information about mutated genes, patient demographics, and modality. The data set also...

    Subject
    DNA Mutational Analysis
    Oncogene Proteins, Fusion
    Receptor Protein-Tyrosine Kinases
    Receptor, trkA
    Receptor, trkB
    Receptor, trkC
    Access Rights
    Free to All
  • Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial

    Authors
    Burman, Bharat
    Jain, Swati
    Fitzgerald, Conall W.R.
    Sherman, Eric J.
    22 more author(s)...
    Description

    Description from Zenodo: "This is a de-identified dataset accompanying the Nature Medicine publication titled "Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial", by Vos et al. (DOI: https://doi.org/10.1038/s41591-023-02518-x). It contains the clinical features and processed data of 64 patients with salivary gland cancer, treated with nivolumab and ipilimumab immunotherapy....

    Subject
    Clinical Trial, Phase II
    Immunotherapy
    Ipilimumab
    Nivolumab
    Salivary Gland Neoplasms
    Access Rights
    Free to All
  • Determinants of Response to Nivolumab plus Ipilimumab in a Phase II Trial of Advanced Salivary Gland Cancer Patients

    Description

    Description from BioProject: "Salivary gland cancers (SGCs) are rare, aggressive cancers that lack effective treatments in the metastatic setting. We report the clinical results and immunogenomic correlates of response from a phase II trial evaluating nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) in metastatic SGC patients."

    Subject
    Clinical Trial, Phase II
    Exome Sequencing
    Ipilimumab
    Nivolumab
    RNA-Seq
    Salivary Gland Neoplasms
    Access Rights
    Free to All